EQRX Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (8 nov 2023 @ 22:00):

EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States...

Stats
Dagens volum	11.93M
Gjennomsnittsvolum	2.95M
Markedsverdi	1.14B
EPS	$-0.180 ( 2023-11-09 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.25
ATR14	$0.0660 (2.82%)

Insider Trading

Date	Person	Action	Amount	type
2023-11-09	Casdin Eli	Sell	5 488 164	Common Stock
2023-11-09	Casdin Eli	Sell	8 110 001	Warrants to purchase Class A Common Stock (right to buy)
2023-11-09	Casdin Eli	Sell	755 766	Earn-out Shares
2023-11-09	Casdin Eli	Sell	101 010	Stock Option (Right to Buy)
2023-11-09	Nallicheri Melanie	Buy	626 999	Common Stock

INSIDER POWER
-96.20
Last 94 transactions
Buy: 76 186 838 \| Sell: 93 441 879

Volum Korrelasjon

Lang: 0.04 (neutral)

Kort: -0.25 (neutral)

Signal:(55.606) Neutral

EQRx, Inc. Korrelasjon

10 Mest positive korrelasjoner
BSRR	0.931
MPAA	0.931
CLGN	0.931
ENG	0.929
CPTN	0.927
VBTX	0.926
MYFW	0.926
UBFO	0.925
SFNC	0.924
BPYPN	0.924

10 Mest negative korrelasjoner
RMBS	-0.899
LYTS	-0.898
CCRC	-0.895
KE	-0.894
ISDX	-0.893
JMPNZ	-0.893
PPYAU	-0.892
IEUS	-0.891
LRFC	-0.89
HEWG	-0.89

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

EQRx, Inc. Korrelasjon - Valuta/Råvare

0.56
( weak )

0.00
( neutral )

0.41
( neutral )

-0.44
( neutral )

-0.38
( neutral )

EQRx, Inc. Økonomi

Annual	2022
Omsetning:	$0
Bruttogevinst:	$0 (0.00 %)
EPS:	$0.430

FY	2022
Omsetning:	$0
Bruttogevinst:	$0 (0.00 %)
EPS:	$0.430

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-0.205

FY	2020
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-0.513

Financial Reports:

No articles found.

EQRx, Inc.

EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); and Sugemalimab, an anti-programmed death-ligand 1 antibody for the treatment of Stage III and Stage IV NSCLC. Its other programs in pipeline include clinical and pre-clinical stage assets, which comprise Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor, which is in Phase II clinical trials in patients with metastatic breast cancer; EQ176, an anti-programmed death-1 antibody that is in Phase III trials for the treatment of patients with primary liver cancer; and EQ121, a selective janus kinase-1 inhibitor that is in various Phase I trials. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.